Re‐admission during · Adults with acute asthma
Adults: higher dose/longer course showed no clear difference in re‐admission in compared with lower dose/shorter course (low certainty).
1 finding from 1 review
Asthma severity and symptoms · Adults with acute asthma
1 finding from 1 review
Asthma symptoms Complete resolution by day 28 · Adults with acute asthma
Adults: higher dose/longer course showed no clear difference in asthma symptoms Complete resolution by day 28 compared with lower dose/shorter course (low certainty).
1 finding from 1 review
Exacerbations · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes new exacerbation in compared with lower dose/shorter course (very low certainty).
2 findings from 1 review
FEV1 % predicted · Adults with acute asthma
1 finding from 1 review
All adverse events · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes all adverse events compared with lower dose/shorter course (very low certainty).
1 finding from 1 review
Re‐admission during · children with acute asthma
1 finding from 1 review
Asthma symptoms · children with acute asthma
Children: higher dose/longer course showed no clear difference in asthma symptoms Symptom free by 7 days compared with lower dose/shorter course (moderate certainty).
1 finding from 1 review
Serious adverse events · children with acute asthma
1 finding from 1 review
Exacerbations · children with acute asthma
Children: higher dose/longer course showed no clear difference in new exacerbation during compared with lower dose/shorter course (low certainty).
2 findings from 1 review
FEV1 % predicted · children with acute asthma
1 finding from 1 review
All adverse events · children with acute asthma
Children: higher dose/longer course showed no clear difference in all adverse events compared with lower dose/shorter course (moderate certainty).
1 finding from 1 review
Intervention not reported
Clinical failure—primary outcome (by intention‐to‐treat analysis) · children with chronic cough of unknown origin lasting longer than 4 weeks
The intervention probably leads to lower clinical failure—primary outcome (by intention‐to‐treat analysis) (moderate certainty).
1 finding from 1 review
Intervention not reported
PC‐QOL mean score at 6 weeks PC‐QOL is a 27‐item questionnaire. Each question has a 7‐point score ranging from 1 (worst quality of life) to 7 (best quality of life). Scores for each item were added and the average taken · children with chronic cough of unknown origin lasting longer than 4 weeks
The intervention probably leads to higher PC‐QOL mean score at 6 weeks PC‐QOL is a 27‐item questionnaire. Each… (moderate certainty).
1 finding from 1 review
Intervention not reported
Duration of cough post randomisation · children with chronic cough of unknown origin lasting longer than 4 weeks
The intervention showed no clear difference in duration of cough post randomisation (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of adverse events experienced · children with chronic cough of unknown origin lasting longer than 4 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Proportions of participants experiencing adverse events or complications · children with chronic cough of unknown origin lasting longer than 4 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate